Calculated plasma volume status and outcomes in patients undergoing transcatheter aortic valve replacement
Open Access
- 5 March 2021
- journal article
- research article
- Published by Wiley in ESC Heart Failure
- Vol. 8 (3), 1990-2001
- https://doi.org/10.1002/ehf2.13270
Abstract
Aims This study investigated the prognostic value of plasma volume status (PVS) in patients who underwent transcatheter aortic valve replacement (TAVR). Methods and results Plasma volume status was calculated in 2588 patients who underwent TAVR using data from the Japanese multicentre registry. All-cause mortality and heart failure hospitalization (HFH) within 2 years of TAVR were compared among the PVS quartiles (Q1, PVS < 5.5%; Q2, PVS 5.5-13.5%; Q3, PVS 13.5-21.0%; and Q4, PVS >= 21.0%). Subgroups were stratified by the PVS cut-off value combined with the New York Heart Association (NYHA) class as follows: low PVS with NYHA I/II (n = 959), low PVS with NYHA III/IV (n = 845), high PVS with NYHA I/II (n = 308), and high PVS with NYHA III/IV (n = 476). The cumulative all-cause mortality and HFH within 2 years of TAVR significantly increased with increasing PVS quartiles [8.5%, 16.8%, 19.2%, and 27.0% (P < 0.001) and 5.8%, 8.7%, 10.3%, and 12.9% (P < 0.001), respectively]. The high-PVS group regardless of the NYHA class had a higher all-cause mortality and HFH [9.6%, 18.2%, 24.5%, and 30.4% (P < 0.001) and 6.1%, 10.4%, 14.1%, and 11.3% (P < 0.001)]. In a Cox regression multivariate analysis, the PVS values of Q3 and Q4 had independently increased all-cause mortality [hazard ratio (HR), 1.50 and 1.64 (P = 0.017 and P = 0.008), respectively], and Q4 had independently increased HFH (HR, 1.98, P = 0.005). The low PVS with NYHA III/IV, high PVS with NYHA I/II, and high PVS with NYHA III/IV also had significantly increased all-cause mortality [HR, 1.45, 1.73, and 1.86 (P = 0.006, P = 0.002, and P < 0.001), respectively] and HFH [HR, 1.52, 2.21, and 1.70 (P = 0.049, P = 0.002, and P = 0.031), respectively]. Conclusions Plasma volume status is useful for predicting all-cause mortality and HFH after TAVR.Keywords
Funding Information
- Daiichi Sankyo Company
- Abbott Japan
- Boston Scientific Corporation
- Medtronic
- Edwards Lifesciences
This publication has 27 references indexed in Scilit:
- Transcatheter and Surgical Aortic Valve Replacement in Patients With Recent Acute Heart FailureThe Annals of Thoracic Surgery, 2020
- Incidence, Prognostic Impact, and Predictive Factors of Readmission for Heart Failure After Transcatheter Aortic Valve ReplacementJACC: Cardiovascular Interventions, 2017
- Thirty-Day Readmissions After Transcatheter Aortic Valve Replacement in the United States Insights From the Nationwide Readmissions DatabaseCirculation: Cardiovascular Interventions, 2016
- Futility, Benefit, and Transcatheter Aortic Valve ReplacementJACC: Cardiovascular Interventions, 2014
- Transcatheter versus Surgical Aortic-Valve Replacement in High-Risk PatientsThe New England Journal of Medicine, 2011
- Transcatheter Aortic-Valve Implantation for Aortic Stenosis in Patients Who Cannot Undergo SurgeryThe New England Journal of Medicine, 2010
- Percutaneous Transcatheter Implantation of an Aortic Valve Prosthesis for Calcific Aortic StenosisCirculation, 2002
- The regulation and measurement of plasma volume in heart failureJournal of the American College of Cardiology, 2002
- Prognostic Importance of Elevated Jugular Venous Pressure and a Third Heart Sound in Patients with Heart FailureThe New England Journal of Medicine, 2001
- Edema of cardiac origin. Studies of body water and sodium, renal function, hemodynamic indexes, and plasma hormones in untreated congestive cardiac failure.Circulation, 1989